Evaluation of the skin carcinogenicity of the TRPV1 antagonist motugivatrep (SJP-0132) using an ultra-short-term two-stage skin carcinogenesis assay in Tg-rasH2 mice Authors: Yoshinori Yamagiwa, Mayumi Kawabe, Yuko Doi, Shingo Nemoto, Ikuyo Atsumi Published: 2026 ABSTRACT Abstract Motugivatrep (SJP-0132), a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist, is being developed as an ophthalmic drug for dry eye disease. Since the role of TRPV1 antagonists in skin carcinogenesis remains controversial, this study aimed to investigate whether motugivatrep promotes skin tumorigenesis using an ultra-short-term two-stage skin carcinogenesis model with Tg-rasH2 mice. Following initiation with a single dermal application of 7,12-dimethylbenz[a]anthracene, motugivatrep was applied topically at doses of 0, 150, 300, or 750 µg/50 µL/animal once a day to mouse skin for 7 weeks. The positive control group received 12-O-tetradecanoylphorbol-13-acetate (TPA) once weekly. No skin tumors or preneoplastic lesions were observed in any animals treated with motugivatrep. In contrast, treatment with TPA significantly increased skin tumor formation, confirming the validity of the assay. These results indicated that motugivatrep lacked skin tumor promotion activity in this Tg-rasH2 mice model, providing safety information regarding dermal exposure to motugivatrep.Keywords: Tg-rasH2 mouse, skin carcinogenicity, skin tumor initiation-promotion model, transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist, motugivatrep Transient receptor potential cation channel subfamily V member 1 (TRPV1) is a nociceptive cation channel that was initially identified in sensory nerve endings1, and is activated by capsaicin, noxious heat, and acidic conditions2, 3. TRPV1 is also expressed in various cells in the skin such as epidermis, Langerhans cells, endothelial and smooth muscle cells of skin blood vessels, and mast cells4, 5. Some studies have suggested a potential role for TRPV1 in skin carcinogenesis6. Capsaicin, a selective TRPV1 agonist, has been shown to act as a co-carcinogen in rodent skin7. Conversely, AMG9810, a TRPV1 antagonist, has been reported to promote tumor development via EGFR signaling pathway8. However, another TRPV1 antagonist, PAC-14028 (asivatrep), did not induce skin tumor formation or EGFR activation9, 10. Thus, the role of TRPV1 in skin carcinogenesis remains uncertain and warrants further investigation. Motugivatrep (SJP-0132) is a TRPV1 antagonist being developed for the treatment of dry eye disease via ocular instillation11. Following ocular administration, the drug is exposed to the ocular surface and may occasionally come into contact with the surrounding periocular skin. Eye drop formulations sometimes cause adverse effects on the periocular area, including the skin12. Since contact with carcinogens on the skin can potentially lead to tumor formation, the potential for skin carcinogenicity needs to be assessed. To date, no evidence of genotoxicity has been found for motugivatrep in either in vitro or in vivo studies13. In addition, motugivatrep did not show carcinogenicity following oral administration to Tg-rasH2 mice for 6 months and to rats for 2 years13. However, its potential to promote carcinogenicity in the skin remains unknown. The promotion of dermal carcinogenicity can be assessed using Tg-rasH2 mice through dermal application of test substances following pretreatment with a skin carcinogen initiator14, 15. This test system allows for the detection of carcinogenic promotion activity within a 2-month treatment period, offering a significantly shorter evaluation timeline compared with conventional long-term skin carcinogenicity studies. Due to its rapid detection capability, this model presents a promising alternative approach for early screening of dermal tumor promoters. This study aimed to evaluate the tumor-promotion activity of motugivatrep on the skin using an ultra-short-term two-stage skin carcinogenesis assay in Tg-rasH2 mice. The study design is summarized in Table 1. Briefly, the study was based on an ultra-short-term skin initiation-promotion model using Tg-rasH2 mouse14, 15, and was conducted at the DIMS Institute of Medical Science, Inc. (Aichi, Japan). Fifty 6-week-old female specific pathogen-free CB6F1-Tg-rasH2 (Tg-rasH2) mice were purchased from CLEA Japan, Inc. (Shizuoka, Japan) and housed in plastic cages with autoclaved wooden chips at a controlled environment set at 22 ± 3°C and 55 ± 15% relative humidity under a 12-h/12-h light/dark cycle in a conventional animal room. All animals were given ad libitum access to a commercial diet (MF pellet diet; Oriental Yeast Co., Ltd., Tokyo, Japan) and tap water. All experimental procedures were conducted in compliance with institutional guidelines for the management of genetically modified laboratory animals and animal welfare, and the study protocol was reviewed and approved by the Institutional Animal Care and Use Committee. Table 1. Study Design of Skin Carcinogenicity Evaluation of Motugivatrep Using Ultra-short-term Skin Initiation-promotion Model with Tg-rasH2 MiceGroupInitiation phasePromotion phase*Dose frequencyNumber of animalsOnce7 weeksNC12.5 μg / 100 μL, DMBA50 μL of 99.5% Ethanol (Vehicle)Once a day10Low dose0.3% (150 μg / 50 μL) motugivatrepOnce a day10Middle dose0.6% (300 μg / 50 μL) motugivatrepOnce a day10High dose1.5% (750 μg / 50 μL) motugivartrepOnce a day10PC4 μg / 200 μL TPAOnce a week10*Dermal applications were started 1 week after the initiation. NC: negative control; PC: positive control; DMBA: 7,12-Dimethylbenz[a]anthracene, dissolved into acetone; TPA: 2-O-tetradecanoylphorbol-13-acetate, dissolved into dimethyl sulfoxide. Study Design of Skin Carcinogenicity Evaluation of Motugivatrep Using Ultra-short-term Skin Initiation-promotion Model with Tg-rasH2 Mice *Dermal applications were started 1 week after the initiation. NC: negative control; PC: positive control; DMBA: 7,12-Dimethylbenz[a]anthracene, dissolved into acetone; TPA: 2-O-tetradecanoylphorbol-13-acetate, dissolved into dimethyl sulfoxide. Motugivatrep (purity: 100.1%) was supplied by Senju Pharmaceutical Co., Ltd. (Osaka, Japan) to the test facility. Based on a previously conducted dose-range finding study of motugivatrep using non-Tg-rasH2 mice, the high dose used for evaluation of carcinogenicity promotion potential was set at 1.5% (750 µg/50 µL/animal), which represents the upper limit of solubility and the maximum feasible dose. The low and middle doses were set at 0.3% (150 µg/50 µL/animal), which corresponds to the clinically used concentration of the motugivatrep ophthalmic formulation11, and 0.6% (300 µg/50 µL/animal), respectively. The dosing volume of 50 µL exceeded the average ophthalmic drop volume (approximately 40 µL)16 and was sufficient to cover the clipped dorsal skin of Tg-rasH2 mice. One day before initiation, 50 healthy mice were divided into five groups (10 animals/group) based on body weight. For the initiation treatment, 7,12-dimethylbenz[a]anthracene (DMBA; Sigma Aldrich Inc., St. Louis, MO, USA; purity: 96%) was dissolved in acetone (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) and applied to the clipped dorsal skin of Tg-rasH2 mice at 7 weeks of age at a dose of 12.5 μg/100 μL per animal using a micropipette (Microman® M50, Gilson Inc., Middleton, WI, USA). One week after initiation, motugivatrep was dissolved in 99.5% ethanol (FUJIFILM Wako Pure Chemical Corporation), and the solutions were applied to the clipped dorsal skin at concentrations of 0.3%, 0.6%, and 1.5% (150, 300, and 750 µg/50 µL/animal) once daily for 7 weeks. As a negative control, 99.5% ethanol, the vehicle for motugivatrep, was similarly applied to the clipped dorsal skin. As a positive control, the skin tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA: Sigma Aldrich Inc.; purity >99%) was dissolved in dimethyl sulfoxide (FUJIFILM Wako Pure Chemical Corporation) and subsequently diluted in acetone, and the solution was similarly applied to the clipped dorsal skin at a dose of 4 μg/200 μL per animal once weekly for the same period as the motugivatrep treatment. In all animals, the application site was not occluded, and the dorsal skin was clipped once weekly. In all animals, mortality was monitored once daily. Body weight and food consumption were measured once weekly. The number of nodules appearing on the dorsal skin was counted macroscopically once weekly. At the termination of the in-life phase, all animals were anesthetized by inhalation of isoflurane and euthanized by exsanguination via the abdominal aorta. Subsequently, the administration sites on the dorsal skin were examined macroscopically at necropsy. The number of macroscopically visible skin nodules at the administration sites was counted, and the average number of nodules per mouse was calculated. After necropsy, the dorsal skin was removed, sandwiched between filter papers, and fixed in 10% (v/v) neutral-buffered formalin. For all animals, the dorsal skin and all nodules were trimmed, embedded in paraffin, sectioned (2–3 μm), and stained with hematoxylin and eosin. Each nodule on the dorsal skin was histopathologically examined by a board-certified pathologist. Newly observed nodules identified during histopathological examination were added to the counts. If skin nodules or preneoplastic and neoplastic lesions appeared in the motugivatrep-treated group, these values were compared with those in the negative control group. Bartlett’s test was performed at a 5% significance level to evaluate the homogeneity of variance. If the variance was homogeneous, the data were analyzed using Dunnett’s multiple comparison test (two-sided). If not, Steel’s test (two-sided), was applied. For the positive control group, data were tested for homogeneity using the F-test before comparison with the negative control group. If the variance was homogeneous, the data were analyzed using Student’s t-test (two-sided); otherwise, Aspin–Welch’s t-test (two-sided) was used. During the treatment period, no mortality was observed in any animals across all groups. Body weight and food consumption increased in the positive control group compared with those in the negative control group, but not in the motugivatrep-treated groups. No abnormal findings were observed in the dorsal skin of the negative control and motugivatrep-treated groups during the treatment period or at necropsy (Fig. 1, Table 2). In the positive control group, animals bearing skin nodule appeared from 5 weeks after DMBA treatment (Fig. 1A), and the number of skin nodules per animal increased (Fig. 1B). At necropsy, multiple nodules were observed in the dorsal skin of all mice, and the increase was statistically significant compared with the negative control group. In addition, multiple raised areas of dorsal skin were observed in one mouse in the positive control group. In the histopathological examination, no abnormal findings were observed in the application site of the dorsal skin in the negative control and motugivatrep-treated groups (Fig. 2A, 2B, Table 2). In the positive control group, 22 lesions of squamous cell hyperplasia (Fig. 2C) and 162 lesions of squamous cell papilloma (Fig. 2D) were observed in 9 and 10 mice, respectively, and the increases were statistically significant compared with those in the negative control group. The multiple raised area observed macroscopically was histologically diagnosed as a down-growth type squamous cell papilloma (Fig. 2E). Incidence of animals bearing skin nodules (A) and the average number of skin nodules per animal (B) in Tg-rasH2 mice following DMBA treatment in the ultra-short-term skin initiation-promotion model. No incidence or increase in the number of skin nodules in the vehicle (ethanol, negative control) and motugivatrep-treated (low, middle, and high dose) groups. In the positive control group treated with TPA, skin nodules begin to appear in the animals starting 5 weeks after DMBA treatment, and the number of nodules continues to increase. NC: negative control; PC: positive control; DMBA: 7,12-Dimethylbenz[α]anthracene. Table 2. Summary of Gross Observation and Histopathological Findings in the Back Skin and the Number of Proliferative Lesions in the Skin Carcinogenicity Evaluation of Motugivatrep Using Ultra-short-term Skin Initiation-promotion Model with Tg-rasH2 MiceGroupNegative controlLow doseMiddle doseHigh dosePositive controlInitiationDMBADMBADMBATreatmentEthanolMotugivatrepTPANumber of animals examined1010101010Gross observation at necropsyNo findings101010100Nodule, multiple000010**Raised area, multiple00001Number of skin nodules/animal (Mean ± SD)0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.010.7 ± 7.3**HistopathologyNo abnormal findings101010100Hyperplasia, squamous cell00009Total number of lesions000022Mean ± SD0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.02.2 ± 2.0**Papilloma, squamous cell000010Total number of lesions0000162Mean ± SD0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.016.2 ± 10.9****p≤0.01, Aspin-Welch’s t-test, two-sided. DMBA: 7,12-Dimethylbenz[a]anthracene; TPA: 12-O-tetradecanoylphorbol-13-acetate; SD: standard deviation. Summary of Gross Observation and Histopathological Findings in the Back Skin and the Number of Proliferative Lesions in the Skin Carcinogenicity Evaluation of Motugivatrep Using Ultra-short-term Skin Initiation-promotion Model with Tg-rasH2 Mice **p≤0.01, Aspin-Welch’s t-test, two-sided. DMBA: 7,12-Dimethylbenz[a]anthracene; TPA: 12-O-tetradecanoylphorbol-13-acetate; SD: standard deviation. Representative photomicrographs of the dorsal skin of Tg-rasH2 mice in the ultra-short-term skin initiation-promotion model. No abnormal findings are observed in skin treated with ethanol (vehicle, A) or motugivatrep (B). In the positive control treated with TPA, squamous cell hyperplasia (C) and papilloma (D) are observed. In one mouse of the positive control group, in which multiple raised areas are observed at necropsy, the lesion is diagnosed as a squamous cell papilloma of down-growth type (E). Hematoxylin and eosin staining. Scale bars=50 µm (A, B, C) or 200 µm (D, E). TPA: 12-O-tetradecanoylphorbol-13-acetate. This study investigated the skin carcinogenicity promotion potential of motugivatrep using an ultra-short-term skin carcinogenesis assay in Tg-rasH2 mice. Throughout the study period, no treatment-related macroscopic or histopathological evidence of skin tumors was observed, even at the maximum feasible dose. In contrast, the positive control group treated with TPA exhibited the development of skin nodules five weeks after DMBA initiation. These lesions were histopathologically confirmed as squamous cell hyperplasia or squamous cell papilloma, consistent with previous reports14. In Tg-rasH2 mice, the incidence of spontaneous skin tumors is known to be very low17–19. These facts indicated that these proliferative lesions in the positive control group were related to treatment of TPA, supporting the validity of this model. Taken together, these results suggested that motugivatrep does not possess skin tumor-promoting activity in the Tg-rasH2 mouse model under the conditions of this study. The Tg-rasH2 mouse is a hemizygous transgenic model carrying the human c-Ha-ras gene, produced by mating transgenic C57BL/6J males with wild-type BALB/CByJ females20. TRPV1, a receptor relevant to the pharmacological activity of motugivatrep, is known to be expressed in the dorsal root ganglia of both C57BL/6 and BALB/C mice21. Although the expression in the skin of Tg-rasH2 mice was not investigated, the background of their generation suggests that TRPV1 is also functional in Tg-rasH2 mice derived from these two strains, and on-target effects of TRPV1 antagonists may be evaluated in this model. The two-stage skin carcinogenesis mouse models are classical and widely accepted methods for investigating the skin carcinogenic potential of chemicals22–26. In fact, a two-stage skin carcinogenesis mouse model was employed in a study to assess the carcinogenic promotion potential of another TRPV1 antagonist, PAC-140289. In these two-stage mouse models, the duration of the test substance treatment phase is shorter than that of classical mouse carcinogenicity studies but extends for more than 20 weeks following initiation. The required duration of the test period in the ultra-short-term two-stage skin carcinogenicity assay using Tg-rasH2 mice employed in the present study is within 8 weeks, which is significantly shorter than that of these two-stage mouse models. Thus, this ultra-short-term model may be useful for the preliminary evaluation of carcinogenic potentials of drug candidates, particularly during the discovery phase of drug development. When combined with genotoxicity data, carcinogenic risks may be assessed based on a weight-of-evidence approach. Motugivatrep was negative for genotoxicity, and no carcinogenicity was observed in subsequent systemic carcinogenicity studies in rasH2 mice and rats13. This study demonstrates the utility of this model for assessing skin carcinogenic potential within a relatively short period when integrated with genotoxicity testing. This carcinogenicity evaluation approach may contribute to the acceleration of safety evaluations in drug development, particularly for compounds with low genotoxic potential but suspected skin carcinogenic risks. There are several limitations to this study. The dosing volume of motugivatrep was set at 50 µL, whereas that of TPA, used as a positive control, was set at 200 µL. In previous studies, dermal application volumes of test compounds were set at 100 or 200 µL14, 15. Although motugivatrep was applied across the clipped dorsal skin, its carcinogenic potential at higher doses than those used in this study remains unclear. In addition, no functional or mechanistic analyses were performed to evaluate the effects of motugivatrep on gene or protein expression in the skin in the present study. The dermal carcinogenic potential of TRPV1 antagonists has been investigated in previous studies with gene and protein expression outcomes. Investigation of the potential of the TRPV1 antagonist AMG9810 in hairless mice provided evidence that AMG9810 activated dermal EGFR/Akt/mTOR signaling, and the authors concluded that TRPV1 antagonism may promote skin carcinogenesis through activation of this signaling pathway8. However, another TRPV1 antagonist, PAC-14028, did not increase skin tumor formation in pre-DMBA-treated female ICR mice, and no activation of the EGFR/Akt/mTOR pathway was observed following its topical application9. Although motugivatrep did not induce visible skin tumors under the experimental conditions, molecular events related to carcinogenesis, such as early changes in gene or protein expression, including effects on the EGFR/Akt/mTOR signaling pathway, remain unclear. Further studies involving molecular profiling and pathway analysis are warranted to comprehensively assess the carcinogenic potential of motugivatrep and other TRPV1 antagonists. In summary, the development of skin nodule was not observed in the motugivatrep-treated groups even at the maximum feasible dose in the ultra-short-term two-stage carcinogenicity assay using the Tg-rasH2 mouse model. These results indicate that motugivatrep lacks skin tumor promotion activity in this model. The result of this study provides safety information regarding dermal exposure to motugivatrep. Author Contributions YY designed the study and drafted this manuscript. MK and YD assisted with the experimental design and conducted the study. All authors, including SN and IA, reviewed this manuscript. Disclosure of Potential Conflicts of Interest The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Acknowledgments The authors thank the staff of the DIMS Institute of Medical Science Inc. for their efforts in conducting the entire study. Their dedication and excellent work made these investigations possible. The authors are also grateful to Dr. Masaaki Kurata for assistance in conducting this study and for providing an informative review of this manuscript. References